![]() ![]() Positive Phase 3 data for DELTA1 trial for delgocitinib, a topical pan-JAK inhibitor for treatment of chronic hand eczema, meeting primary and all key secondary endpoints.LEO Pharma’s R&D pipeline progressed significantly in 2022 and achieved important milestones to support future growth. Growth partly off-set by a decline in the Thrombosis business due to supply challenges on our production site in the beginning of the year and reduced revenue from contract manufacturing of divested products. Growth was driven by 8% growth in the dermatology portfolio in constant currency rates. Excluding transformation and restructuring costs adjusted EBITDA loss was 1,253 mDKK. The EBITDA loss represents an improvement of 383 mDKK vs. Operating loss (EBIT) ended at 3,311 mDKK and is in line with the guidance of an operating loss (EBIT) of 3.1-3.3 bDKK announced beginning of 2022. ![]() The revenue growth in constant currency rates was 4% and in-line with guidance of 3-5% for the year. 2022 was a year dominated by execution of growth strategy, simplifying operations, advancing the pipeline and launching Adtralza®/Adbry™.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |